rs1799977 — MLH1 Ile219Val

MLH1 Ile219Val — A Common ATPase Domain Variant with Intact Repair Function

MLH1 (mutL homolog 1) is a cornerstone of the DNA mismatch repair (MMR) system¹¹ DNA mismatch repair (MMR) system
A proofreading pathway that detects and corrects replication errors — particularly base mismatches and small insertions/deletions — before they become heritable mutations, the cellular proofreading machinery that catches errors after DNA replication. MLH1 heterodimerizes with PMS2 to form MutLα, which acts as the "decision-maker" complex that couples mismatch recognition (by MutSα/MutSβ) with excision and repair. Loss of MLH1 function is the defining molecular event in Lynch syndrome — the most common hereditary colorectal cancer syndrome — and in a subset of sporadic microsatellite-unstable cancers. MLH1 also plays a distinct, essential role in meiotic recombination²² meiotic recombination
The controlled exchange of DNA between paired homologous chromosomes during egg and sperm formation; MLH1 marks and stabilizes the sites where chromosomes will cross over, where MLH1-MLH3 marks the sites where homologous chromosomes will exchange DNA during formation of eggs and sperm.

The Ile219Val variant (c.655A>G, p.Ile219Val) substitutes valine for isoleucine at position 219 — a conserved buried hydrophobic residue within the N-terminal ATPase domain. It is the most frequent exonic polymorphism in MLH1³³ most frequent exonic polymorphism in MLH1
Tournier et al. 2004, Hum Mutat — identified as the most common MLH1 coding variant across European cohorts, present in roughly one in three Europeans. Despite its location in a functionally critical domain, multiple lines of evidence classify it as benign with respect to mismatch repair capacity.

The Mechanism

Position 219 sits within the N-terminal ATPase domain of MLH1⁴⁴ N-terminal ATPase domain of MLH1
Residues 1–347 constitute the ATPase "GHKL" domain, which binds and hydrolyzes ATP to drive conformational changes required for mismatch repair and coordination of downstream repair factors. Isoleucine and valine are both nonpolar, aliphatic residues with similar side-chain volumes — valine is simply two methylene groups shorter. This conservative substitution at a buried hydrophobic position makes structural disruption unlikely.

Plotz et al.⁵⁵ Plotz et al.
Plotz G et al. Evaluation of the MLH1 I219V alteration in DNA mismatch repair activity and ulcerative colitis. Int J Colorectal Dis, 2008 performed in silico structural analysis and quantitative biochemical assays and found "identical stability and activity of the protein" compared to wild-type MLH1. The variant was described as "unlikely to abolish MLH1 function but may modulate it" — a subtle distinction that has guided subsequent functional research. The same conclusion was reached independently by Vogelsang et al.⁶⁶ Vogelsang et al.
Vogelsang M et al. Assessing pathogenicity of MLH1 variants by co-expression of human MLH1 and PMS2 genes in yeast. Int J Cancer, 2009, who classified I219V as non-pathogenic in a yeast co-expression assay with human PMS2.

The word "modulate" in the Plotz conclusion — not "abolish" — leaves open the possibility that the Val allele introduces subtle kinetic differences in ATPase cycling. The ATPase activity of MLH1 drives the conformational changes that open and close the MutLα clamp during mismatch repair. If Val219 alters ATP hydrolysis rates marginally without impairing repair altogether, this could manifest as altered repair efficiency under high mutation burden — a context relevant to chemotherapy response and rapidly proliferating cells.

In meiosis, MLH1 marks approximately 90% of obligate crossover sites⁷⁷ 90% of obligate crossover sites
MLH1 foci on meiotic chromosomes visualized by immunofluorescence correspond to crossover events that ensure proper chromosome segregation; each chromosome pair needs at least one crossover to segregate correctly on meiotic chromosomes. Whether subtle Val219 modulation of ATPase activity affects crossover placement or efficiency has not been directly studied.

The Evidence

For Lynch syndrome: the InSiGHT expert panel has reviewed this variant and classified it as Benign⁸⁸ classified it as Benign
ClinVar VCV000036557, reviewed by InSiGHT 2013; 30+ consistent submitters all classifying as benign or likely benign; high population frequency cited as key evidence based on high population frequency, functional data, and presence in unaffected individuals. Chen et al.⁹⁹ Chen et al.
Chen H et al. Association between MutL homolog 1 polymorphisms and the risk of colorectal cancer: a meta-analysis. J Cancer Res Clin Oncol, 2015 confirmed this in a meta-analysis of 29,114 individuals: rs1799977 showed no association with colorectal cancer risk in any of four genetic models tested.

The picture is more nuanced in other cancer contexts. A meta-analysis of breast cancer¹⁰¹⁰ meta-analysis of breast cancer
Zhang Q et al. Association of Polymorphisms of Mismatch Repair Genes hMLH1 and hMSH2 with Breast Cancer Susceptibility. Crit Rev Eukaryot Gene Expr, 2020 (9 hMLH1 studies) found that the G allele (GA+GG genotype) was associated with increased breast cancer susceptibility, particularly in Caucasian women. Mechanistically, this could reflect subtle repair modulation under high replication stress in rapidly dividing breast epithelium — a different context from the colon.

Most striking is the DLBCL survival data: Rossi et al.¹¹¹¹ Rossi et al.
Rossi D et al. The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. Blood, 2011 found that MLH1 rs1799977 AG/GG genotype independently predicted overall survival in DLBCL (HR=3.23, P<0.001) and predicted inferior response to R-CHOP21 (HR=2.02) and platinum-based therapy (HR=2.26). This likely reflects the role of intact MLH1 in processing alkylating agent and platinum-induced DNA damage¹²¹² alkylating agent and platinum-induced DNA damage
Chemotherapy agents like doxorubicin and cisplatin create DNA damage that stalls replication; cells with efficient MMR recognize and respond to this damage differently than MMR-impaired cells — the very "modulation" Plotz described may amplify under chemotherapy-level DNA damage load.

Campbell et al.¹³¹³ Campbell et al.
Campbell PT et al. Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut, 2009 (n=1,609 cases, 1,972 controls) found no independent colon cancer association but identified a statistically significant interaction between the Ile219Val genotype and Western diet consumption (p=0.03) — suggesting the variant's functional modulation may emerge specifically under dietary conditions that increase DNA damage or alter repair demands.

Practical Implications

This variant does not cause Lynch syndrome and does not require Lynch syndrome surveillance protocols. For the great majority of carriers, it is a benign common polymorphism. The actionable considerations are:

For cancer screening: Standard colorectal cancer screening at age 45 applies — this variant does not change that schedule. The potential breast cancer signal is modest and population-based, not individually predictive.

For chemotherapy-treated patients: The DLBCL survival data is the most clinically significant finding. Carriers receiving DNA-damaging chemotherapy may have altered treatment responses — oncologists treating AG/GG carriers for DLBCL or other chemosensitive cancers should be aware of this pharmacogenomic context.

For gamete quality: MLH1's meiotic crossover function means that any modulation of ATPase activity could theoretically affect crossover placement or number. Direct evidence for fertility effects of this specific variant is lacking, but in the context of assisted reproduction (IVF/ICSI), awareness of MLH1 variant status is emerging as potentially relevant to gamete quality assessment.

Interactions

EXO1 rs72755295: EXO1 (exonuclease 1) is the primary resection enzyme in MLH1-directed mismatch excision, and also cooperates with MLH1-MLH3 in meiotic crossover resolution. Approximately 80% of meiotic crossovers require both MLH1-MLH3 endonuclease activity and EXO1 function. The EXO1 rs72755295 G allele increases EXO1 expression and is associated with earlier menopause. A carrier of both the MLH1 Ile219Val G allele (potentially modulating ATPase kinetics) and the EXO1 rs72755295 G allele (increasing excision capacity) could have an imbalanced MLH1-EXO1 stoichiometry in meiotic cells. No published study has directly assessed this combination.

MLH1 rs1800734 (-93G>A): The promoter variant in the same gene. rs1800734 reduces MLH1 expression; rs1799977 modulates protein function. A carrier of both the promoter A allele (reduced expression) and the coding G allele (Val219) would have both quantitatively less and functionally subtly different MLH1 — a compound state that no single-variant analysis captures. The Plotz and Vogelsang functional studies assessed I219V in isolation; combined effects have not been studied.

DLBCL chemotherapy context: The strong survival signal in DLBCL (Rossi et al.) suggests that under high-intensity DNA damage (R-CHOP21, platinum compounds), the I219V modulation becomes clinically significant. This interaction with chemotherapy is arguably the highest- evidence actionable finding from this variant.